Protagen is applying its biomarker discovery platform, SeroTag® to detect autoantibodies in individuals undergoing cancer immunotherapy, to help predict treatment response and guide therapeutic decisions.
Immuno-Oncology: Response Prediction
Protagen applies its biomarker discovery platform, SeroTag®, to detect autoantibody signatures in patient serum for better disease profiling and response prediction within two therapeutic areas: immuno-oncology and autoimmune disease.
Patient Stratification - NavigAID
Protagen’s NavigAID portfolio of patient stratification arrays enables the classification of different patient subgroups for response prediction in indications such as SSc, SLE, RA, SjS, which will soon be expanded into immuno-oncology.
Immuno-Oncology: Adverse Events Detection
SeroTag® allows for the detection of autoantibody profiles indicative of immune-related adverse events (irAEs) in patients undergoing immunotherapies, which supports patient management and treatment decisions.
Protagen Precision Diagnostics
Protagen specializes in Pharma development services, novel diagnostics and companion diagnostics, in the fields of immuno-oncology and autoimmune disease. Using its proprietary SeroTag® biomarker discovery platform and its portfolio of NavigAID patient stratification products, Protagen identifies valuable biomarkers that support pharmaceutical development and personalized treatment with targeted therapies. Utilizing pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies.
Autoimmune and Immuno-oncology
The ability to stratify patients into different disease subgroups based on the individual molecular characteristics of each subtype can drive better drug development and improve the success rate of clinical trials. Protagen’s SeroTag® technology has been applied in the development of the NavigAID portfolio of patient stratification arrays for autoimmune indications such as SSc. SLE, RA and SJS.
Protagen’s SeroTag® technology is also being applied to the field of immuno-oncology where it is helping pharmaceutical and biotechnology companies to address, identify and monitor a number of issues currently hindering the successful development and broader application of certain cancer immunotherapies, such as low response rates and immune-related adverse events (irAEs) and the onset of autoimmune disease. Protagen also aims to develop NavigAID for immuno-oncology application.